Press Releases Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 11/03/2026 GMT			5-day change	1st Jan Change
1.370 ^USD	-2.84%		0.00%	-8.05%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Press Releases

02-18	Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
01-26	Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology	AQ
01-06	Marker Therapeutics - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer	AQ
01-05	Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer	AQ
11-14	Marker Therapeutics : Corporate Presentation	PU
11-14	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates	AQ
11-05	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors	AQ
11-03	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting	AQ
06/10/25	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program	AQ
28/08/25	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
26/08/25	Marker Therapeutics : Corporate Presentation	PU
26/08/25	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma	AQ
30/07/25	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference	AQ
17/06/25	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma	AQ
04/06/25	Marker Therapeutics : Corporate Presentation	PU
20/05/25	Marker Therapeutics : Lymphodepletion Enhances MAR-T Cell Response in Lymphoma	PU
20/05/25	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	AQ
19/05/25	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies	AQ
01/04/25	Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference	AQ
31/03/25	Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results	AQ
25/02/25	Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference	AQ
19/12/24	Marker Therapeutics : Provides a Clinical Update on MT 601 in Patients with Lymphoma Form 8 K	PU
19/12/24	Marker Therapeutics Announces $16.1 Million Private Placement	AQ
19/12/24	Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma	AQ
17/12/24	Marker Therapeutics : Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT 601 in Patients with Pancreatic Cancer Form 8 K	PU